BCOR and myelodysplastic syndrome: Mutations in epigenetic modifiers that alter haematopoietic differentiation have been shown to co-operate with dysregulated growth factor signalling to drive oncogenic transformation22,35 and BCOR mutations co-occur with RAS pathway mutations in both AML and MDS patients2,36,37.